Sunpaweravong Somkiat, Puttawibul Puttisak, Sunpaweravong Patrapim, Nitiruangjaras Anupong, Boonyaphiphat Pleumjit, Kemapanmanus Marisa
J Med Assoc Thai. 2016 Mar;99(3):331-7.
Squamous cell carcinoma antigen (SCCA) and CYFRA 21-1 have been reported as useful tumor markers for esophageal squamous cell carcinoma (ESCC), but no information has yet been reported about the relationship between these serum tumor markers and tissue proliferative activity (Ki-67) in ESCC patients.
To study the correlation between SCCA, CYFRA 21-1, Ki-67, and clinicopathological factors in ESCC patients.
Pretreatment SCCA and CYFRA 21-1 serum levels were measured, while the expression of Ki-67 was assessed on tumor tissue. The associations between these biomarkers, clinicopathological factors, and overall survival were analyzed.
One hundred sixty six patients participated in this study. Elevated SCCA and CYFRA 21-1 were found in 78.9% and 50.0% of the patients, respectively, while 42.8% had both serum markers elevated. The SCCA and CYFRA 21-1 levels were not correlated (p = 0.128) to each other nor to age, sex, T N, M location, grade, or Ki-67. High Ki-67 expression levels were significantly correlated with T4 (p = 0.010), M1 (p = 0.010), and poor grade (p = 0.015) but not to age, sex, N, or location. Levels of SCCA, CYFRA 21-1, and Ki-67, alone or in any combination, were not correlated to survival of patients.
The authors showed that Ki-67 in tumor tissue is probably a more reliable marker than serum SCCA and CYFRA 21-1 in predicting the clinical course of ESCC.
鳞状细胞癌抗原(SCCA)和细胞角蛋白19片段(CYFRA 21-1)已被报道为食管鳞状细胞癌(ESCC)有用的肿瘤标志物,但关于这些血清肿瘤标志物与ESCC患者组织增殖活性(Ki-67)之间的关系尚无报道。
研究ESCC患者中SCCA、CYFRA 21-1、Ki-67与临床病理因素之间的相关性。
检测治疗前SCCA和CYFRA 21-1血清水平,同时评估肿瘤组织中Ki-67的表达。分析这些生物标志物、临床病理因素与总生存期之间的关联。
166例患者参与本研究。分别有78.9%和50.0%的患者SCCA和CYFRA 21-1升高,42.8%的患者两种血清标志物均升高。SCCA和CYFRA 21-1水平彼此之间以及与年龄、性别、T分期、N分期、M分期、部位、分级或Ki-67均无相关性(p = 0.128)。高Ki-67表达水平与T4期(p = 0.010)、M1期(p = 0.010)和低分级(p = 0.015)显著相关,但与年龄、性别、N分期或部位无关。SCCA、CYFRA 21-1和Ki-67水平单独或联合均与患者生存期无关。
作者表明,肿瘤组织中的Ki-67在预测ESCC临床进程方面可能比血清SCCA和CYFRA 21-1更可靠。